Latest Updates
Promising new drug for acute myeloid leukaemia
A new drug in clinical trials has the potential to improve the survival rate of patients with acute myeloid leukaemia.
Melanoma revealing its secrets
Professor Nikolas Haass and his team are unlocking the secrets of melanoma cells to identify better treatments for the cancer.
New drug to beat chemo resistance in ovarian cancer
In a preclinical study, researchers find low doses of a drug can overcome chemotherapy resistance in an ovarian cancer sub-type.
An Australian-first initiative of 'bench to bedside' medical research
The Translational Research Institute (TRI) is a unique, Australian-first initiative of ‘bench to bedside’ medical research. TRI combines clinical and translational research to advance progress from laboratory discovery to application in the community.
The work conducted at TRI is translational research, a research process which involves teams of patients, clinicians and researchers working together to solve health challenges faster. The work is driven by the needs of patients, a question formed by a clinician and a solution sought by a scientist.
What is Translational Research?
Also known as 'bench-to-bedside' research, it is a type of medical research that focusses on 'translating' basic science discoveries from the laboratory into the clinic.
The aim is to improve how we detect, diagnose and treat health conditions, and improve health outcomes for patients.
At TRI, we work to develop new treatments and diagnostics for conditions ranging from various cancers to autoimmune diseases, and translate these discoveries into improved healthcare.
What's On
ASSC Skin & Skin Cancer Seminar
This series looks at providing insights into the latest skin and skin cancer research field, while also featuring...
DIRECTORS’ CHOICE SERIES
A new four part series covering various topics related to publishing in 2020!
